2021 Fiscal Year Final Research Report
Alzheimer's disease related biomarkers in progressive supranuclear palsy
| Project/Area Number |
19K07991
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 52020:Neurology-related
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | 進行性核上性麻痺 / PSP / 脳脊髄液 / CSF / バイオマーカー / Aβ / tau |
|---|
| Outline of Final Research Achievements |
In the cerebrospinal fluid (CSF) of patients with progressive supranuclear palsy (PSP), β-amyloid (Aβ), which is an Alzheimer's disease-related molecule, is lower than that of healthy elderly. In Alzheimer's disease, only Aβ42 consisting of 42 amino acids is decreased, whereas in PSP, in addition to Aβ42, Aβ38 and Aβ40, which reflect the production of Aβ in the brain and the transfer to CSF, are also decreased. In the PSP model in which mutant tau is expressed in cultured cells, Aβ production (processing) is reduced. Taken together, because the expression of pathogenic tau in PSP reduces Aβ production, the finding that all Aβ species are reduced in CSF could be an useful diagnostic biomarker for PSP.
|
| Free Research Field |
脳神経内科学
|
| Academic Significance and Societal Importance of the Research Achievements |
進行性核上性麻痺(PSP)は人口10万人あたり10～20人程度の比較的稀な神経変性疾患である。PSPの診断はこれまで病歴、神経学的診察、MRIなどの脳形態画像により行われてきたが、病初期の診断は症状および脳萎縮が軽度のため困難であった。今回の研究成果から、脳脊髄液中のβアミロイド(Aβ)の発現パターンを確認することで、より正確なPSPの診断が可能になることが期待される。
|
